Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFlorida International University
About this trial
The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the gut), immune system, and the brain functioning in people living with HIV.
Eligibility criteria
Qualifiers
Age 18 or older
Speaks and reads English
Verified HIV+ status with antiretroviral medications bearing his/her name
Current diagnosis on Major Depressive Disorder (MDD) using a structured clinical interview (DIAMOND) or Hamilton Rating Scale for Depression scores of 7 or greater
Disqualifiers
Unable to provide informed consent
Active, untreated major mental illness
Pregnancy at baseline
Received CBT for depression in the past 2 years
Trial design
Treatments tested in this trial
- Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)
- Antiretroviral Therapy (ART) Adherence Counseling
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Florida International University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov